These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29964008)

  • 1. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
    Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway.
    Wang XJ; Feng CW; Li M
    Mol Cell Biochem; 2013 Aug; 380(1-2):57-66. PubMed ID: 23625205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of YEATS4 by miR-218 sensitizes colorectal cancer cells to L-OHP-induced cell apoptosis by inhibiting cytoprotective autophagy.
    Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S
    Oncol Rep; 2016 Dec; 36(6):3682-3690. PubMed ID: 27779719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100A6 mediated epithelial-mesenchymal transition affects chemosensitivity of colorectal cancer to oxaliplatin.
    Zhang C; Zeng M; Xu Y; Huang B; Shi P; Zhu X; Cao Y
    Gene; 2024 Jul; 914():148406. PubMed ID: 38521111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Anthraquinone Derivative C2 Enhances Oxaliplatin-Induced Cell Death and Triggers Autophagy via the PI3K/AKT/mTOR Pathway.
    Li Y; Yan W; Qin Y; Zhang L; Xiao S
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADAM17-siRNA inhibits MCF-7 breast cancer through EGFR-PI3K-AKT activation.
    Meng X; Hu B; Hossain MM; Chen G; Sun Y; Zhang X
    Int J Oncol; 2016 Aug; 49(2):682-90. PubMed ID: 27221510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-κB pathway.
    Sui H; Pan SF; Feng Y; Jin BH; Liu X; Zhou LH; Hou FG; Wang WH; Fu XL; Han ZF; Ren JL; Shi XL; Zhu HR; Li Q
    BMC Complement Altern Med; 2014 Aug; 14():279. PubMed ID: 25085593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
    Zhang HR; Chen JM; Zeng ZY; Que WZ
    J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation.
    Zheng X; Jiang F; Katakowski M; Zhang ZG; Lu QE; Chopp M
    Cancer Biol Ther; 2009 Jun; 8(11):1045-54. PubMed ID: 19395875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling.
    Wang R; Ye X; Bhattacharya R; Boulbes DR; Fan F; Xia L; Ellis LM
    Stem Cells Transl Med; 2016 Mar; 5(3):331-8. PubMed ID: 26744411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CircAGFG1 absence decreases PKM2 expression to enhance oxaliplatin sensitivity in colorectal cancer in a miR-7-5p-dependent manner.
    Chen J; Wang H; Tang M
    J Chemother; 2024 May; 36(3):208-221. PubMed ID: 37691430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smad4 sensitizes colorectal cancer to 5-fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade.
    Zhang B; Leng C; Wu C; Zhang Z; Dou L; Luo X; Zhang B; Chen X
    Oncol Rep; 2016 Mar; 35(3):1807-15. PubMed ID: 26647806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitrogen permease regulator-like 2 enhances sensitivity to oxaliplatin in colon cancer cells.
    Liu MN; Liu AY; Du YJ; Pei FH; Wang XH; Chen J; Liu D; Liu BR
    Mol Med Rep; 2015 Jul; 12(1):1189-96. PubMed ID: 25777765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].
    Zhang XJ; Zhang L; Liu YP; Xu HM; Sun P; Song JG; Luo YH
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):181-6. PubMed ID: 23879997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOA5 alleviates reactive oxygen species to promote oxaliplatin resistance in PIK3CA-mutated colorectal cancer.
    Liu YL; Xiang Z; Zhang BY; Zou YW; Chen GL; Yin L; Shi YL; Xu LL; Bi J; Wang Q
    Aging (Albany NY); 2024 Jun; 16(11):9410-9436. PubMed ID: 38848145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway.
    Lin P; Sun X; Feng T; Zou H; Jiang Y; Liu Z; Zhao D; Yu X
    Mol Cell Biochem; 2012 Jan; 359(1-2):235-43. PubMed ID: 21837402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystatin SA attenuates gastric cancer cells growth and increases sensitivity to oxaliplatin via PI3K/AKT signaling pathway.
    Lu Y; Wang H; Chen S; Yang B; Li Y; Li Y
    J Cancer Res Clin Oncol; 2024 May; 150(5):244. PubMed ID: 38717526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of ADAM17 modulation in gastric cancer through regulation of the EGFR and TNF-α signalling pathways.
    Sun J; Jiang J; Lu K; Chen Q; Tao D; Chen Z
    Mol Cell Biochem; 2017 Feb; 426(1-2):17-26. PubMed ID: 27878499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatty acid synthase regulates proliferation and migration of colorectal cancer cells via HER2-PI3K/Akt signaling pathway.
    Li N; Bu X; Tian X; Wu P; Yang L; Huang P
    Nutr Cancer; 2012 Aug; 64(6):864-70. PubMed ID: 22860766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.